9 completed, 3 terminated, 1 unknown. 4 Phase 2, 3 Phase 3, 2 Not applicable, 2 Phase 1, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 3 | Completed 1, Terminated 1, Unknown 1 |
| Not applicable | 2 | Completed 1, Terminated 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 2 |
Follow ferumoxtran-10: new trials by email Literature Review of ferumoxtran-10 trials Research Report on ferumoxtran-10
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ferumoxtran-10-enhanced MRI in Prostate Cancer Patients Ferrotran® (Ferumoxtran-10) - Prostate Cancer, Metastasis | Phase 3 | Terminated | Saving Patients' Lives Medical B.V. | 172 | 2020-05-27 | 2026-04-28 |
| Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination Clariscan, Gadolinium-Based Contrast Agents - Magnetic Resonance Imaging (MRI) | Completed | GE Healthcare | 2118 | 2018-12-17 | 2019-12-04 | |
| Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose Gadoterate (Dotarem/Clariscan), Gadobutrol (Gadavist/Gadovist, BAY86-4875) - Magnetic Resonance Imaging | Phase 4 | Completed | Bayer | 157 | 2018-11-14 | 2021-06-14 |
| Nano MRI on 7 Tesla in Rectal and Breast Cancer ferumoxtran-10, 7 Tesla MRI, 3 Tesla MRI - Rectal Neoplasms, Breast Neoplasms | Phase 3 | Unknown | Radboud University Medical Center | 30 | 2015-06-01 | 2018-12-06 |
| Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer Ferumoxytol - Esophageal Neoplasms | Not applicable | Completed | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 41 | 2014-09-01 | 2019-01-16 |
| Metabolic Imaging in Carotid Atherosclerosis USPIO (ferumoxytol)-enhanced MRI scan, 18f-Fluoride PET/CT scan, 18F-Flurodeoxyglucose PET/CT scan - Atherosclerosis, Stroke | Completed | University of Edinburgh | 26 | 2012-10-10 | 2024-05-02 | |
| Pre-Operative Staging of Pancreatic Cancer Using Superparamagnetic Iron Oxide Magnetic Resonance Imaging (SPIO MRI) Superparamagnetic Iron Oxide Magnetic Resonance Imaging - Pancreatic Cancer | Phase 4 | Completed | Massachusetts General Hospital | 35 | 2008-07-01 | 2017-07-25 |
| Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer fludeoxyglucose F 18, positron emission tomography, computed tomography - Cervical Adenocarcinoma, Cervical Adenosquamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 384 | 2007-09-01 | 2019-07-23 |
| USPIO-enhanced and Diffusion-weighted MRI for the Detection of Pelvic Lymph Node Metastases Imaging: diffusion-weighted MRI, Sinerem (USPIO) enhanced MRI - Prostate Cancer, Bladder Cancer | Phase 3 | Completed | Insel Gruppe AG, University Hospital Bern | 130 | 2007-09-01 | 2011-10-12 |
| Magnetic Resonance Imaging Using Ferumoxtran-10 in Finding Metastases to the Axillary Lymph Nodes in Patients With Breast Cancer ferumoxtran-10, magnetic resonance imaging, sentinel lymph node biopsy - Breast Cancer | Phase 2 | Completed | Virginia Commonwealth University | 3 | 2005-09-01 | 2010-05-03 |
| A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast Ferumoxtran-10 (USPIO), MR lymphangiography - Bladder Cancer, Genitourinary Cancer | Not applicable | Terminated | M.D. Anderson Cancer Center | 10 | 2005-07-01 | 2012-08-07 |
| Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide MRI contrast agent Combidex (ferumoxtran-10) - Uterine Neoplasms, Cervix Neoplasms | Phase 1 / Phase 2 | Completed | University Health Network, Toronto | 61 | 2004-04-01 | 2022-10-07 |
| Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation Ferumoxtran-10 (Combidex), Neurosurgery - Brain Neoplasms | Phase 2 | Terminated | OHSU Knight Cancer Institute | 116 | 2000-08-01 | 2022-12-21 |
Prostatic Neoplasms (4) · Urinary Bladder Neoplasms (3) · Breast Neoplasms (2) · Uterine Cervical Neoplasms (2) · Atherosclerosis (1) · Brain Neoplasms (1) · Breast Neoplasms, Male (1) · Calcinosis (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Inflammation (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1) · Stroke (1)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Bayer (1) · GE Healthcare (1) · Insel Gruppe AG, University Hospital Bern (1) · M.D. Anderson Cancer Center (1) · Massachusetts General Hospital (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1) · Radboud University Medical Center (1) · Saving Patients' Lives Medical B.V. (1) · University Health Network, Toronto (1) · University of Edinburgh (1) · Virginia Commonwealth University (1)
United States (6) · Germany (3) · Netherlands (3) · Switzerland (3) · Canada (2) · South Korea (2) · United Kingdom (2) · Belgium (1) · France (1) · Italy (1) · Japan (1) · Norway (1)
David E Newby, DSc (1) · Edward A Neuwelt, MD (1) · Haesun Choi, MD (1) · Hanneke WM van Laarhoven, MD, PhD (1) · Harriet C Thoeny, MD (1) · Karen A. Kurdziel, MD (1) · Michael Milosevic, MD (1) · Mostafa Atri (1) · Ralph Weissleder, MD, PhD (1) · Tom Scheenen, PhD (1)
PMID 19144456, PMID 23084842, PMID 23916692, PMID 34133205
2018 (1), P30CA016059 (1), R01NS034608 (1), U10CA027469 (1), U10CA180868 (1)